IFNG and hemophagocytic syndrome: Novel targeted therapeutic approaches like the anti-IFN-γ monoclonal antibody, JAK1/2 inhibitor which is shown to be effective in primary HLH (51, 52) can be considered in patients with FA especially with elevated cytokine levels.